Characteristic | Toripalimab plus IMRT N=25 |
Sex | |
Female | 7 (28.0%) |
Male | 18 (72.0%) |
Age, years | |
Median | 49.0 |
IQR | 43.5–52.5 |
Karnofsky performance status score | |
90–100 | 25 (100.0%) |
70–80 | 0 (0.0%) |
Smoking status | |
Smokers | 2 (8.0%) |
Non-smokers | 23 (92.0%) |
Histology | |
Non-keratinizing undifferentiated (type III) | 23 (92.0%) |
Non-keratinizing differentiated (type II) | 2 (8.0%) |
EBV DNA copy number | |
Median | 77.5 |
IQR | 0–382.5 |
Primary T classification | |
T1 | 3 (12.0%) |
T2 | 6 (24.0%) |
T3 | 9 (36.0%) |
T4 | 7 (28.0%) |
Primary N classification | |
N0 | 1 (4.0%) |
N1 | 7 (28.0%) |
N2 | 16 (64.0%) |
N3 | 1 (4.0%) |
Primary M classification | |
M0 | 25 (100.0%) |
M1 | 0 (0.0%) |
Chemotherapy during primary therapy | |
Yes | 24 (96.0%) |
No | 1 (4.0%) |
Recurrent T classification | |
T2 | 2 (8.0%) |
T3 | 16 (64.0%) |
T4 | 7 (28.0%) |
Recurrent N classification | |
N0 | 16 (64.0%) |
N1 | 9 (36.0%) |
Recurrent M classification | |
M0 | 25 (100.0%) |
M1 | 0 (0.0%) |
Recurrent stage | |
II | 2 (8.0%) |
III | 16 (64.0%) |
IVa | 7 (28.0%) |
PRANCIS prognostic index | |
Low risk | 17 (68.0%) |
High risk | 8 (32.0%) |
Disease-free interval, median months (IQR) | 37.0 (21.5–73.0) |
Previous radiotherapy | |
No | 0 (0.0%) |
Yes | 25 (100.0%) |
Data are presented as the median or n (%) unless otherwise stated.
EBV, Epstein-Barr virus; IMRT, intensity-modulated radiotherapy ; PRANCIS, Predicting Radioresistant Nasopharynx Carcinoma Survival.